4.0 Article

Erythrocyte adducin: A structural regulator of the red blood cell membrane

Journal

TRANSFUSION CLINIQUE ET BIOLOGIQUE
Volume 17, Issue 3, Pages 87-94

Publisher

ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
DOI: 10.1016/j.tracli.2010.05.008

Keywords

Erythrocyte adducin; Erythrocyte membrane; beta-adducin; alpha-adducin; gamma-adducin; Adducin's function; Adducin's regulation

Funding

  1. NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM024417] Funding Source: NIH RePORTER
  2. NIGMS NIH HHS [R01 GM024417] Funding Source: Medline

Ask authors/readers for more resources

Adducin is an alpha, beta heterotetramer that performs multiple important functions in the human erythrocyte membrane First adducin forms a bridge that connects the spectrin-actin junctional complex to band 3, the major membrane-spanning potent in the bilayer Rupture of this bridge leads to membrane instability and spontaneous fragmentation Second. adducin caps the fast growing (bat bed) end of actin filaments. preventing the tetradecameric protofilaments from elongating into macroscopic F-actin microfilaments Third. adducin stabilizes the association between actin and spectrin, assuring that the junctional complex remains intact during the mechanical distortions experienced by the circulating cell And finally. adducin responds to stimuli that may be important in regulating the global properties of the cell, possibly including: cation transport. cell morphology and membrane deformability The text below summarizes the structural properties of adducin. its multiple functions in erythrocytes. and the consequences of engineered deletions of each of adducin subunits in transgenic mice (C) 2010 Elsevier Masson SAS All rights reserved

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.0
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Biochemical Research Methods

Synthesis and Evaluation of a Novel 64Cu- and 67Ga-Labeled Neurokinin 1 Receptor Antagonist for in Vivo Targeting of NK1R-Positive Tumor Xenografts

Hanwen Zhang, Ananda Kumar Kanduluru, Pooja Desai, Afruja Ahad, Sean Carlin, Nidhi Tandon, Wolfgang A. Weber, Philip S. Low

BIOCONJUGATE CHEMISTRY (2018)

Article Biochemical Research Methods

New Mechanism for Release of Endosomal Contents: Osmotic Lysis via Nigericin-Mediated K+/H+ Exchange

Loganathan Rangasamy, Venkatesh Chelvam, Ananda Kumar Kanduluru, Madduri Srinivasarao, N. Achini Bandara, Fei You, Esteban A. Orellana, Andrea L. Kasinski, Philip S. Low

BIOCONJUGATE CHEMISTRY (2018)

Article Biochemical Research Methods

Targeted Tubulysin B Hydrazide Conjugate for the Treatment of Luteinizing Hormone-Releasing Hormone Receptor-Positive Cancers

Jyoti Roy, Miranda Kaake, Madduri Sriniyasarao, Philip S. Low

BIOCONJUGATE CHEMISTRY (2018)

Article Medicine, Research & Experimental

Development of a Small Molecule Tubulysin B Conjugate for Treatment of Carbonic Anhydrase IX Receptor Expressing Cancers

Isaac S. Marks, Spencer S. Gardeen, Sarah J. Kurdziel, Sonia T. Nicolaou, J. Evan Woods, Sumith A. Kularatne, Philip S. Low

MOLECULAR PHARMACEUTICS (2018)

Article Chemistry, Medicinal

Application of Sequential Palladium Catalysis for the Discovery of Janus Kinase Inhibitors in the Benzo[c]pyrrolo[2,3-h][1,6]naphthyridin-5-one (BPN) Series

Mohamed S. A. Elsayed, Jeffery J. Nielsen, Sungtae Park, Jeongho Park, Qingyang Liu, Chang H. Kim, Yves Pommier, Keli Agama, Philip S. Low, Mark Cushman

JOURNAL OF MEDICINAL CHEMISTRY (2018)

Article Chemistry, Multidisciplinary

Analysis of the bone fracture targeting properties of osteotropic ligands

Jeffery J. Nielsen, Stewart A. Low, Neal T. Ramseier, Rahul Hadap, Nicholas A. Young, Mingding Wang, Philip S. Low

Summary: The study aimed to improve bone fracture management by continuously applying bone anabolic agents to the fracture surface. Short oligopeptides of acidic amino acids were found to significantly increase localization of peptide payload to bone fractures, offering a promising strategy for enhancing fracture healing.

JOURNAL OF CONTROLLED RELEASE (2021)

Article Biochemistry & Molecular Biology

Syk Kinase Inhibitors Synergize with Artemisinins by Enhancing Oxidative Stress in Plasmodium falciparum-Parasitized Erythrocytes

Ioannis Tsamesidis, Karine Reybier, Giuseppe Marchetti, Maria Carmina Pau, Patrizia Virdis, Claudio Fozza, Francoise Nepveu, Philip S. Low, Francesco Michelangelo Turrini, Antonella Pantaleo

ANTIOXIDANTS (2020)

Article Biochemical Research Methods

Design of Neuraminidase-Targeted Imaging and Therapeutic Agents for the Diagnosis and Treatment of Influenza Virus Infections

Xin Liu, Weichuan Luo, Boning Zhang, Yong Gu Lee, Imrul Shahriar, Madduri Srinivasarao, Philip S. Low

Summary: In this study, a modified influenza virus neuraminidase inhibitor, zanamivir, was utilized for diagnostic, imaging, and therapeutic purposes in influenza virus infections. Different conjugates like the zanamivir-conjugated rhodamine dye and zanamivir99 mTc radioimaging conjugate were designed for visual monitoring of virus-infected cells. Moreover, targeted cytotoxic drugs and CAR T cells were developed specifically for viral neuraminidase-expressing cells, showing potential for improved treatment of influenza virus infections.

BIOCONJUGATE CHEMISTRY (2021)

Article Biochemistry & Molecular Biology

Design of a Near Infrared Fluorescent Ureter Imaging Agent for Prevention of Ureter Damage during Abdominal Surgeries

Sakkarapalayam M. Mahalingam, Karson S. Putt, Madduri Srinivasarao, Philip S. Low

Summary: The inadvertent severing of a ureter during colorectal surgeries is a common issue, leading to the development of new near-infrared dyes to help surgeons identify ureter location. The new PEGylated UreterGlow derivatives show promising optical and biodistribution characteristics, making them good candidates for translation into the clinic.

MOLECULES (2021)

Article Chemistry, Multidisciplinary

Design, Synthesis, and Targeted Delivery of an Immune Stimulant that Selectively Reactivates Exhausted CAR T Cells

John Victor Napoleon, Boning Zhang, Qian Luo, Madduri Srinivasarao, Philip S. Low

Summary: Administering a CAR-targeted TLR7 agonist can reverse CAR T cell exhaustion and successfully treat solid tumors.

ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2022)

Article Oncology

Targeted Rejuvenation of Exhausted Chimeric Antigen Receptor T Cells Regresses Refractory Solid Tumors

Qian Luo, John Napoleon, Xin Liu, Boning Zhang, Suilan Zheng, Philip S. Low

Summary: This study describes a strategy to reverse CAR T-cell exhaustion by using a universal anti-fluorescein CAR that engages multiple cancer cell clones and acts as a drug-internalizing receptor. By attaching a Toll-like receptor 7 agonist to the anti-fluorescein CAR, they downregulate exhaustion markers and reactivate exhausted CAR-T cells, leading to regression of solid tumors.

MOLECULAR CANCER RESEARCH (2022)

Article Engineering, Biomedical

Engineered human pluripotent stem cell-derived natural killer cells with PD-L1 responsive immunological memory for enhanced immunotherapeutic efficacy

Yun Chang, Gyuhyung Jin, Weichuan Luo, Qian Luo, Juhyung Jung, Sydney N. Hummel, Sandra Torregrosa-Allen, Bennett D. Elzey, Philip S. Low, Xiaojun Lance Lian, Xiaoping Bao

Summary: Adoptive CAR-engineered NK cells have potential for cancer treatment, but limited immunological memory and donor cell availability hinder their applications. We evaluated different CAR constructs to enhance NK cell proliferation and anti-tumor cytotoxicity. We genetically engineered hPSCs with optimized CARs and differentiated them into dual CAR-NK cells. The memory-like hPSC-NK cells showed enhanced anti-tumor activity through antigen-dependent activation of signaling pathways. Our modular hPSC CAR-NK engineering platform is a realistic strategy for off-the-shelf CAR-NK cells with immunological memory-like phenotype for targeted immunotherapy.

BIOACTIVE MATERIALS (2023)

Article Immunology

Imatinib augments standard malaria combination therapy without added toxicity

Huynh Dinh Chien, Antonella Pantaleo, Kristina R. Kesely, Panae Noomuna, Karson S. Putt, Tran Anh Tuan, Philip S. Low, Francesco M. Turrini

Summary: The coadministration of imatinib with standard of care (SOC) in uncomplicated P. falciparum malaria patients led to a faster decline in parasite density and fever, without any delayed parasite clearance. The improvements were most significant in patients with the highest parasite density, where serious complications and death are most common.

JOURNAL OF EXPERIMENTAL MEDICINE (2021)

Article Multidisciplinary Sciences

A universal dual mechanism immunotherapy for the treatment of influenza virus infections

Xin Liu, Boning Zhang, Yingcai Wang, Hanan S. Haymour, Fenghua Zhang, Le-cun Xu, Madduri Srinivasarao, Philip S. Low

NATURE COMMUNICATIONS (2020)

Article Chemistry, Multidisciplinary

Targeting of a Photosensitizer to the Mitochondrion Enhances the Potency of Photodynamic Therapy

Sakkarapalayam M. Mahalingam, Josue D. Ordaz, Philip S. Low

ACS OMEGA (2018)

No Data Available